Skip to content

Released May 22, 2023, before the open

10-K filed May 22, 2023, 52 days after period end · 0001764013-23-000065

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$59.43MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$55,793,000N/M
Free Cash Flowderived-$55,819,000N/M

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2018
Net Income-$59.43M-$47.17M-$450.00
EPS Diluted——$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR